

Patient Name :	Bill Date :
DOB/Age/Gender :	Sample Collected :
Patient ID / UHID :	Sample Received :
Referred By :	Report Date :
Sample Type :	Barcode No :
Client :	Report Status :

CYTOGENETICS REPORT
CLL Panel By FISH

Clinical Indication Cytogenetics Study for CLL

FISH Probe Used CLL FISH panel (del 11q22.3, +12, del 17p13.1, del 13q14.2), FISH probes from Healthcare Biotechnology

FISH Probe : LSI ATM (11q22.3) orange probe, CEP11 Green probe

	Total number of cells scored	200
	Cells with Normal Pattern	200
	Cells with Abnormal Pattern	00

Loci Analyzed	Signal Pattern	Normal Cut Off (%)	Percentage of Cells showing signal pattern	Result
ATM/CEP11	2O/2G	>= 2 %	100%	Negative

FISH Probe : LSI RB1 (13q14.2) green color probe

	Total number of cells scored	200
	Cells with Normal Pattern	200
	Cells with Abnormal Pattern	00

Loci Analyzed	Signal Pattern	Normal Cut Off (%)	Percentage of Cells showing signal pattern	Result
RB1	2G	>= 2 %	100%	Negative



Dr. Ashish Fauzdar
 PhD (Genetics), AIIMS
 Head of Clinical Genomics & Cytogenetics

Patient Name :	Bill Date :
DOB/Age/Gender :	Sample Collected :
Patient ID / UHID :	Sample Received :
Referred By :	Report Date :
Sample Type :	Barcode No :
Client :	Report Status :

FISH Probe : LSI P53 (17p13.1) spectrum orange / CEP17 spectrum green

	Total number of cells scored	200
	Cells with Normal Pattern	150
	Cells with Abnormal Pattern	50

Loci Analyzed	Signal Pattern	Normal Cut Off (%)	Percentage of Cells showing signal pattern	Result
P53/CEP17	1O/2G	>= 2 %	25%	POSITIVE
P53/CEP17	2O/2G	>= 2 %	75%	Negative

FISH Probe : CEP12 spectrum orange

	Total number of cells scored	200
	Cells with Normal Pattern	200
	Cells with Abnormal Pattern	00

Loci Analyzed	Signal Pattern	Normal Cut Off (%)	Percentage of Cells showing signal pattern	Result
CEP12	2O	>= 2 %	100%	Negative

ISCN Nomenclature **nuc ish(P53x1,CEP17)[50/200], (ATMx2,CEP11x2,RB1x2,CEP12x2)[200]**
(As per International System of Human Cytogenomic Nomenclature, ISCN, 2020)

Interpretation The patient sample is **positive** for *p53* gene (17p) gene deletion. *p53* gene deletion has a incidence of 10-20% in B-cell CLL and is associated with disease invasiveness and poor prognosis and indicated as a high risk disease refractory to chemotherapy. Other genetic markers screened in CLL panel for the patient including *RB1*, *ATM* gene and *CEP 12* were screened negative with no abnormality in all the cells analyzed.

Result This case is considered as positive with abnormal signal pattern observed for *p53* gene deletion in **25%** of the total cells screened.
(FISH is not intended for use as a standalone test for making clinical decisions)



Ashish Fauzdar
Dr. Ashish Fauzdar
 PhD (Genetics), AIIMS
 Head of Clinical Genomics & Cytogenetics

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.